161 related articles for article (PubMed ID: 30737544)
1. Does Drug-Eluting Bead TACE Enhance the Local Effect of IRE? Imaging and Histopathological Evaluation in a Porcine Model.
Isfort P; Rauen P; Na HS; Ito N; von Stillfried S; Kuhl C; Bruners P
Cardiovasc Intervent Radiol; 2019 Jun; 42(6):880-885. PubMed ID: 30737544
[TBL] [Abstract][Full Text] [Related]
2. Mapping Drug Dose Distribution on CT Images Following Transarterial Chemoembolization with Radiopaque Drug-Eluting Beads in a Rabbit Tumor Model.
Mikhail AS; Pritchard WF; Negussie AH; Krishnasamy VP; Amchin DB; Thompson JG; Wakim PG; Woods D; Bakhutashvili I; Esparza-Trujillo JA; Karanian JW; Willis SL; Lewis AL; Levy EB; Wood BJ
Radiology; 2018 Nov; 289(2):396-404. PubMed ID: 30106347
[TBL] [Abstract][Full Text] [Related]
3. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
Wu B; Zhou J; Ling G; Zhu D; Long Q
World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
[TBL] [Abstract][Full Text] [Related]
4. Electrochemical Effects after Transarterial Chemoembolization in Combination with Percutaneous Irreversible Electroporation: Observations in an Acute Porcine Liver Model.
Vollherbst D; Bertheau RC; Fritz S; Mogler C; Kauczor HU; Ryschich E; Radeleff BA; Pereira PL; Sommer CM
J Vasc Interv Radiol; 2016 Jun; 27(6):913-921.e2. PubMed ID: 27103147
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin-loaded drug-eluting beads versus conventional transarterial chemoembolization for nonresectable hepatocellular carcinoma.
Arabi M; BenMousa A; Bzeizi K; Garad F; Ahmed I; Al-Otaibi M
Saudi J Gastroenterol; 2015; 21(3):175-80. PubMed ID: 26021777
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Texture Analysis Parameter for Response Prediction in Patients with Hepatocellular Carcinoma Undergoing Drug-eluting Bead Transarterial Chemoembolization (DEB-TACE) Using Biphasic Contrast-enhanced CT Image Data: Correlation with Liver Perfusion CT.
Kloth C; Thaiss WM; Kärgel R; Grimmer R; Fritz J; Ioanoviciu SD; Ketelsen D; Nikolaou K; Horger M
Acad Radiol; 2017 Nov; 24(11):1352-1363. PubMed ID: 28652049
[TBL] [Abstract][Full Text] [Related]
7. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
[TBL] [Abstract][Full Text] [Related]
8. Parenchymal Blood Volume Assessed by C-Arm-Based Computed Tomography in Immediate Posttreatment Evaluation of Drug-Eluting Bead Transarterial Chemoembolization in Hepatocellular Carcinoma.
Syha R; Grözinger G; Grosse U; Maurer M; Zender L; Horger M; Nikolaou K; Ketelsen D
Invest Radiol; 2016 Feb; 51(2):121-6. PubMed ID: 26488373
[TBL] [Abstract][Full Text] [Related]
9. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.
Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Huang K; Zhou Q; Wang R; Cheng D; Ma Y
J Gastroenterol Hepatol; 2014 May; 29(5):920-5. PubMed ID: 24224722
[TBL] [Abstract][Full Text] [Related]
11. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
[TBL] [Abstract][Full Text] [Related]
12. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma].
Ferrer Puchol MD; la Parra C; Esteban E; Vaño M; Forment M; Vera A; Cosín O
Radiologia; 2011; 53(3):246-53. PubMed ID: 21295802
[TBL] [Abstract][Full Text] [Related]
14. Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study.
Lee S; Kim KM; Lee SJ; Lee KH; Lee DY; Kim MD; Kim DY; Kim SU; Won JY
Acta Radiol; 2017 Feb; 58(2):131-139. PubMed ID: 27217418
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
Lencioni R; Llovet JM; Han G; Tak WY; Yang J; Guglielmi A; Paik SW; Reig M; Kim DY; Chau GY; Luca A; Del Arbol LR; Leberre MA; Niu W; Nicholson K; Meinhardt G; Bruix J
J Hepatol; 2016 May; 64(5):1090-1098. PubMed ID: 26809111
[TBL] [Abstract][Full Text] [Related]
16. Immediate post-doxorubicin drug-eluting beads chemoembolization Mr Apparent diffusion coefficient quantification predicts response in unresectable hepatocellular carcinoma: A pilot study.
Kokabi N; Camacho JC; Xing M; Edalat F; Mittal PK; Kim HS
J Magn Reson Imaging; 2015 Oct; 42(4):981-9. PubMed ID: 25683022
[TBL] [Abstract][Full Text] [Related]
17. Does neoadjuvant doxorubicin drug-eluting bead transarterial chemoembolization improve survival in patients undergoing liver transplant for hepatocellular carcinoma?
Dorcaratto D; Udupa V; Hogan NM; Brophy DP; McCann JW; Maguire D; Geoghegan J; Cantwell CP; Hoti E
Diagn Interv Radiol; 2017; 23(6):441-447. PubMed ID: 29063856
[TBL] [Abstract][Full Text] [Related]
18. Computed tomography perfusion imaging for monitoring transarterial chemoembolization of hepatocellular carcinoma.
Marquez HP; Karalli A; Haubenreisser H; Mathew RP; Alkadhi H; Brismar TB; Henzler T; Fischer MA
Eur J Radiol; 2017 Jun; 91():160-167. PubMed ID: 28629564
[TBL] [Abstract][Full Text] [Related]
19. CT-guided irreversible electroporation in an acute porcine liver model: effect of previous transarterial iodized oil tissue marking on technical parameters, 3D computed tomographic rendering of the electroporation zone, and histopathology.
Sommer CM; Fritz S; Vollherbst D; Zelzer S; Wachter MF; Bellemann N; Gockner T; Mokry T; Schmitz A; Aulmann S; Stampfl U; Pereira P; Kauczor HU; Werner J; Radeleff BA
Cardiovasc Intervent Radiol; 2015 Feb; 38(1):191-200. PubMed ID: 24870700
[TBL] [Abstract][Full Text] [Related]
20. Comparison between high-frequency irreversible electroporation and irreversible electroporation ablation of small swine liver: follow-up of DCE-MRI and pathological observations.
Li J; Zhang XB; Wang JJ; Jin LJ; Shan HS; Zhang X; Ma L; Xue XD; Zhang X; Zhang ZL; Meng LL; Yuan F; Xiao YY
Chin Med J (Engl); 2021 Jun; 134(17):2081-2090. PubMed ID: 34172620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
